These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 26553687)

  • 21. Randomized trial to assess immunogenicity and safety of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine in infants.
    Marchant CD; Miller JM; Marshall GS; Blatter M; Aris E; Friedland LR; Boutriau D;
    Pediatr Infect Dis J; 2010 Jan; 29(1):48-52. PubMed ID: 20035207
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans.
    Sow SO; Okoko BJ; Diallo A; Viviani S; Borrow R; Carlone G; Tapia M; Akinsola AK; Arduin P; Findlow H; Elie C; Haidara FC; Adegbola RA; Diop D; Parulekar V; Chaumont J; Martellet L; Diallo F; Idoko OT; Tang Y; Plikaytis BD; Kulkarni PS; Marchetti E; LaForce FM; Preziosi MP
    N Engl J Med; 2011 Jun; 364(24):2293-304. PubMed ID: 21675889
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Persistence of the immune response two years after vaccination with quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) in Asian adolescents.
    Quiambao BP; Jain H; Bavdekar A; Dubey AP; Kolhe D; Bianco V; Van der Wielen M; Miller JM
    Hum Vaccin Immunother; 2016 Aug; 12(8):2162-2168. PubMed ID: 27152501
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of a serogroup A meningococcal conjugate vaccine (PsA-TT) on serogroup A meningococcal meningitis and carriage in Chad: a community study [corrected].
    Daugla DM; Gami JP; Gamougam K; Naibei N; Mbainadji L; Narbé M; Toralta J; Kodbesse B; Ngadoua C; Coldiron ME; Fermon F; Page AL; Djingarey MH; Hugonnet S; Harrison OB; Rebbetts LS; Tekletsion Y; Watkins ER; Hill D; Caugant DA; Chandramohan D; Hassan-King M; Manigart O; Nascimento M; Woukeu A; Trotter C; Stuart JM; Maiden M; Greenwood BM
    Lancet; 2014 Jan; 383(9911):40-47. PubMed ID: 24035220
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Study of a localized meningococcal meningitis epidemic in Burkina Faso: incidence, carriage, and immunity.
    Mueller JE; Yaro S; Njanpop-Lafourcade BM; Drabo A; Idohou RS; Kroman SS; Sanou O; Diagbouga S; Traoré Y; Sangaré L; Borrow R; Gessner BD
    J Infect Dis; 2011 Dec; 204(11):1787-95. PubMed ID: 21998478
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antibody persistence after serogroup C meningococcal conjugate vaccine in children with sickle cell disease.
    Souza AR; Maruyama CM; Sáfadi MA; Lopes MH; Azevedo RS; Findlow H; Bai X; Borrow R; Weckx LY
    Vaccine; 2016 Aug; 34(36):4327-34. PubMed ID: 27395566
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Seroprevalence of bactericidal, specific IgG antibodies and incidence of meningitis due to group A Neisseria meningitidis by age in Burkina Faso 2008.
    Trotter CL; Yaro S; Njanpop-Lafourcade BM; Drabo A; Kroman SS; Idohou RS; Sanou O; Bowen L; Findlow H; Diagbouga S; Gessner BD; Borrow R; Mueller JE
    PLoS One; 2013; 8(2):e55486. PubMed ID: 23457471
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Seroepidemiological Study of Serogroup A Meningococcal Infection in the African Meningitis Belt.
    Manigart O; Trotter C; Findlow H; Assefa A; Mihret W; Moti Demisse T; Yeshitela B; Osei I; Hodgson A; Quaye SL; Sow S; Coulibaly M; Diallo K; Traore A; Collard JM; Moustapha Boukary R; Djermakoye O; Mahamane AE; Jusot JF; Sokhna C; Alavo S; Doucoure S; Ba el H; Dieng M; Diallo A; Daugla DM; Omotara B; Chandramohan D; Hassan-King M; Nascimento M; Woukeu A; Borrow R; Stuart JM; Greenwood B
    PLoS One; 2016; 11(2):e0147928. PubMed ID: 26872255
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunogenicity and safety of a new meningococcal A conjugate vaccine in Indian children aged 2-10 years: a phase II/III double-blind randomized controlled trial.
    Hirve S; Bavdekar A; Pandit A; Juvekar S; Patil M; Preziosi MP; Tang Y; Marchetti E; Martellet L; Findlow H; Elie C; Parulekar V; Plikaytis B; Borrow R; Carlone G; Kulkarni PS; Goel A; Suresh K; Beri S; Kapre S; Jadhav S; Preaud JM; Viviani S; LaForce FM
    Vaccine; 2012 Oct; 30(45):6456-60. PubMed ID: 22898557
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Investigation of serum bactericidal activity in childhood and adolescence 3-6 years after vaccination with a single dose of serogroup C meningococcal conjugate vaccine.
    Sakou II; Tzanakaki G; Tsolia MN; Sioumala M; Barbouni A; Kyprianou M; Papaevangelou V; Tsitsika A; Blackwell CC; Kafetzis D; Kremastinou J
    Vaccine; 2009 Jul; 27(33):4408-11. PubMed ID: 19500554
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Persistence of antibodies for 42 months following vaccination of adolescents with a meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine (MenACWY-TT).
    Østergaard L; Van der Wielen M; Bianco V; Miller JM
    Int J Infect Dis; 2013 Mar; 17(3):e173-6. PubMed ID: 23246368
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety, immunogenicity, and antibody persistence of a new meningococcal group A conjugate vaccine in healthy Indian adults.
    Kshirsagar N; Mur N; Thatte U; Gogtay N; Viviani S; Préziosi MP; Elie C; Findlow H; Carlone G; Borrow R; Parulekar V; Plikaytis B; Kulkarni P; Imbault N; LaForce FM
    Vaccine; 2007 Sep; 25 Suppl 1():A101-7. PubMed ID: 17532101
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of saliva to monitor meningococcal vaccine responses: proposing a threshold in saliva as surrogate of protection.
    van Ravenhorst MB; van der Klis FRM; van Rooijen DM; Sanders EAM; Berbers GAM
    BMC Med Res Methodol; 2019 Jan; 19(1):1. PubMed ID: 30611213
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of the serogroup A meningococcal conjugate vaccine, MenAfriVac, on carriage and herd immunity.
    Kristiansen PA; Diomandé F; Ba AK; Sanou I; Ouédraogo AS; Ouédraogo R; Sangaré L; Kandolo D; Aké F; Saga IM; Clark TA; Misegades L; Martin SW; Thomas JD; Tiendrebeogo SR; Hassan-King M; Djingarey MH; Messonnier NE; Préziosi MP; Laforce FM; Caugant DA
    Clin Infect Dis; 2013 Feb; 56(3):354-63. PubMed ID: 23087396
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Group A antibody persistence five years after meningococcal polysaccharide vaccination in the Sudan.
    Flitter BA; Ismail A; Vu D; Granoff DM
    Hum Vaccin; 2007; 3(4):135-8. PubMed ID: 17581284
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antibody persistence and immune memory 15 months after priming with an investigational tetravalent meningococcal tetanus toxoid conjugate vaccine (MenACWY-TT) in toddlers and young children.
    Knuf M; Baine Y; Bianco V; Boutriau D; Miller JM
    Hum Vaccin Immunother; 2012 Jul; 8(7):866-72. PubMed ID: 22485049
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serogroup A meningococcal conjugate vaccine coverage after the first national mass immunization campaign-Burkina Faso, 2011.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2012 Dec; 61(50):1022-4. PubMed ID: 23254256
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Three-year antibody persistence and safety after a single dose of combined haemophilus influenzae type b (Hib)-Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine in Hib-primed toddlers.
    Booy R; Richmond P; Nolan T; McVernon J; Marshall H; Nissen M; Reynolds G; Ziegler JB; Stoney T; Heron L; Lambert S; Mesaros N; Peddiraju K; Miller JM
    Pediatr Infect Dis J; 2013 Feb; 32(2):169-74. PubMed ID: 23080288
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Salivary antibody levels in adolescents in response to a meningococcal serogroup C conjugate booster vaccination nine years after priming: systemically induced local immunity and saliva as potential surveillance tool.
    Stoof SP; van der Klis FR; van Rooijen DM; Bogaert D; Trzciński K; Sanders EA; Berbers GA
    Vaccine; 2015 Jul; 33(32):3933-9. PubMed ID: 26100925
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Kinetics of the long-term antibody response after meningococcal C vaccination in patients with juvenile idiopathic arthritis: a retrospective cohort study.
    Stoof SP; Heijstek MW; Sijssens KM; van der Klis F; Sanders EA; Teunis PF; Wulffraat NM; Berbers GA
    Ann Rheum Dis; 2014 Apr; 73(4):728-34. PubMed ID: 23505231
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.